Abbonarsi

Is systematic Gadolinium injection relevant during MRI follow-up for non-functioning pituitary macroadenomas? - 25/01/23

Doi : 10.1016/j.neurad.2022.08.003 
Axel Villemaire a, , Gilles Adam a, Hélio Fayolle b, Margaux Roques a, Jean Darcourt a, Philippe Caron c, Fabrice Bonneville a
a Departements of Neuroradiology, CHU Toulouse, Toulouse, France 
b Nuclear Medicine, CHU Toulouse, Toulouse, France 
c Endocrinology-Metabolic and nutrition Diseases, CHU Toulouse, Toulouse, France 

Corresponding author at: Neuroradiology Service, CHU Toulouse Purpan, place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9.Neuroradiology ServiceCHU Toulouse Purpanplace du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9

Abstract

Objective

To compare the performance of coronal contrast-enhanced T1-weighted (ceT1-w) and T2-weighted (T2-w) sequences for diagnosing progression during the MRI follow-up of Non-Functioning Pituitary MacroAdenomas (NFPMAs).

Patients and methods

106 patients, who had at least two MRIs for the follow-up of NFPMA, were enrolled retrospectively. The largest adenoma diameter was measured on coronal ceT1-w sequences and separately on T2-w sequences for all follow-up MRIs. Interobserver variability was also assessed by 2 independent neuroradiologists in a sample series of 100 examinations. Progression was defined by an increase ≥ 2 mm in diameter between 2 MRIs. Progression thresholds of 3 and 4 mm were also tested. The results of ceT1-w and T2-w sequences were analysed for concordance.

Results

93.1% concordance was achieved between ceT1-w and T2-w coronal sequences in 580 follow-up MRIs. In the case of progression detected on at least one sequence, 64.4% concordance was documented for a 2-mm threshold, 87.7% for 3-mm and 97.1% for 4-mm. Discordance was mainly observed on the first postoperative MRI and in case of NFPMAs with multiple recurrences. Kappa was better for diagnosing progression on T2-w than on ceT1-w sequences (0.67 vs. 0.54). It should be noted that 100% agreement was observed between the 2 sequences in the 82 follow-up MRIs of patients with complete surgical resection.

Conclusion

93.1% concordance was achieved for coronal ceT1-w and T2-w sequences during the MRI follow-up of NFPMAs, thus challenging systematic injection of gadolinium. If MRI without gadolinium injection is a first-line option, our results suggest that ceT1-w sequences should be reserved for the first postoperative MRI and for the follow-up of aggressive and recurrent NFPMAs.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Non-secreting pituitary adenoma, Follow-up, Surgery, MRI, Gadolinium injection


Mappa


© 2022  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 50 - N° 1

P. 3-8 - febbraio 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Iodine footprint: Moving towards environmental responsibility
  • Raphel Jomaah, Jean-Alix Barrat, Raphaël Tripier, Julien Ognard, Samy Ammari, Douraied Ben Salem
| Articolo seguente Articolo seguente
  • Dense, deep learning-based intracranial aneurysm detection on TOF MRI using two-stage regularized U-Net
  • Frédéric Claux, Maxime Baudouin, Clément Bogey, Aymeric Rouchaud

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.